Diagnostic assays and methods of use for detection of filarial infection
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsThomas B. Nutman, Doran Fink, Joseph Kubofcik, Peter D. Burbelo
Life of this patent
Estimating the term…
Abstract
The polynucleotide encoding the antigen Wb123 from the filarial nematode Wuchereria bancrofti, the major causative organism of lymphatic filariasis is provided, along with the polypeptide encoded by the polynucleotide. Methods for making the WM23 antigen, recombinant vectors encoding the Wb123 polynucleotide, and methods of detection of the Wb123 antigen through luciferase immunoprecipitation, ELISA and other detection systems are also provided.
Claims10
A method for detecting presence of antibodies to Wuchereria bancrofti or Brugia malayi infective larvae (L3) in a sample, the method comprising:
- a) contacting the sample with a first binding reagent which comprises a fusion protein having a reporter domain and a binding domain, the binding domain comprising Wb123 antigen, and forming an immunocomplex, wherein the Wb123 antigen is encoded by the polynucleotide sequence of SEQ ID NO:
- 1;
- b) contacting the immunocomplex of a) with an immobilized second binding reagent, the second binding reagent being capable of binding to the antibodies if the antibodies are present in the sample, the first and second binding reagents being capable of simultaneously binding to the antibodies if the antibodies are present in the sample, such that the first binding reagent becomes immobilized through the antibodies bound to the second binding reagent;
- c) detecting whether the first binding reagent has become immobilized to detect the presence or concentration of the antibodies;
- and
- d) correlating the detection of the immobilization of the first binding reagent with the presence of antibodies to Wuchereria bancrofti or Brugia malayi infective larvae (L3) in the sample.
A method for detecting exposure to Wuchereria bancrofti or Brugia malayi in a subject, the method comprising:
- a) obtaining a sample from a subject suspected of being exposed to W. bancrofti or B. malayi;
- b) contacting the sample of a) with a mixture comprising a Renilla luciferase fusion protein comprising a Wb123 antigen to form an immunocomplex, wherein the Wb123 antigen is encoded by the polynucleotide sequence of SEQ ID NO:
- 1;
- c) contacting the resulting immunocomplex of b) with a protein A/G binding substrate and binding the protein A/G binding substrate to the immunocomplex;
- d) removing any unbound protein A/G binding substrate;
- e) contacting the immunocomplex from d) with a luciferase substrate and incubating the mixture under conditions suitable to produce luminescence;
- f) measuring the luminescence produced in the sample;
- and
- g) correlating the luminescence produced with exposure to Wuchereria bancrofti or Brugia malayi.
A method for detecting a quantity of a specific antibody to Wb123 antigen in a sample, the method comprising:
- (a) providing a Wb123 antigen which selectively forms a first immunocomplex with a sample antibody, the Wb123 antigen being directly bound to a solid support at a first location, wherein the Wb123 antigen is encoded by the polynucleotide sequence of SEQ ID NO:
- 1;
- (b) providing an antibody which selectively forms a second immunocomplex with a sample antigen, the antibody being directly bound to the solid support at a second location;
- (c) contacting the first location on the solid support with at least a portion of a biological sample under conditions whereby the first immunocomplex can form and contacting the second location on the solid support with at least a portion of the sample under conditions whereby the second immunocomplex can form;
- (d) washing unbound material from the first location and from the second location;
- (e) separately detecting whether the first immunocomplex is formed and whether the second immune complex is formed, the first immunocomplex being detected with a labeled antigen which selectively binds to the first immunocomplex, and the second immunocomplex being detected by adding a labeled antibody which selectively binds to the second complex, the labeled antibody being presented to both the first and the second locations;
- and
- (f) correlating the detection of the amount of labeled antibody being presented to both the first and the second locations with the amount of antibody in the sample.
Dependencies are inferred from the claim text.